| Oct 10 |
bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer
|
| Oct 9 |
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
|
| Sep 18 |
Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis
|
| Sep 12 |
bioAffinity Technologies announces secondary offering of 1.8M shares
|
| Aug 23 |
bioAffinity Technologies CFO Michael Dougherty to depart
|
| Aug 23 |
bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO
|
| Aug 15 |
bioAffinity Technologies GAAP EPS of -$0.19, revenue of $2.4M
|
| Aug 14 |
bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales
|
| Aug 5 |
bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
|
| Aug 2 |
WallachBeth Capital Announces bioAffinity Technologies Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
|
